Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Helen Donners"'
Autor:
Eva Maria Fenyö, Alan Heath, Stefania Dispinseri, Harvey Holmes, Paolo Lusso, Susan Zolla-Pazner, Helen Donners, Leo Heyndrickx, Jose Alcami, Vera Bongertz, Christian Jassoy, Mauro Malnati, David Montefiori, Christiane Moog, Lynn Morris, Saladin Osmanov, Victoria Polonis, Quentin Sattentau, Hanneke Schuitemaker, Ruengpung Sutthent, Terri Wrin, Gabriella Scarlatti
Publikováno v:
PLoS ONE, Vol 4, Iss 2, p e4505 (2009)
Neutralizing antibody assessments play a central role in human immunodeficiency virus type-1 (HIV-1) vaccine development but it is unclear which assay, or combination of assays, will provide reliable measures of correlates of protection. To address t
Externí odkaz:
https://doaj.org/article/fac6af32cdf44af3997336dd753f82d2
Autor:
Peter Vanlandschoot, Sophia Steyaert, Els Beirnaert, Geert Leroux-Roels, Lieven Verhoye, Katrien Fransen, Helen Donners, Guido Vanham, Leo Heyndrickx
Publikováno v:
Journal of immunological methods
Journal of Immunological Methods
Journal of Immunological Methods
The intrasplenic injection of human peripheral blood mononuclear cells (PBMCs) into severely immune deficient NOD/SCID mice, causes a massive and transient dominant expansion of human B cells in the spleen. This permits the easy isolation of human mo
Publikováno v:
Vaccine. 22:104-111
Quantification of human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies is considered to be an important parameter in evaluating candidate vaccines. Most previous studies have failed to detect vaccine-induced antibodies against primary
Autor:
Christian Jassoy, Harvey Holmes, Vera Bongertz, David C. Montefiori, Ruengpung Sutthent, Lynn Morris, Terri Wrin, Paolo Lusso, Christiane Moog, Susan Zolla-Pazner, Gabriella Scarlatti, Stefania Dispinseri, Alan Heath, Victoria R. Polonis, Quentin J. Sattentau, Hanneke Schuitemaker, Saladin Osmanov, José Alcamí, Leo Heyndrickx, Helen Donners, Eva Maria Fenyö, Mauro S. Malnati
Publikováno v:
PLoS ONE
PLoS ONE; 7(5) (2012)
Repisalud
Instituto de Salud Carlos III (ISCIII)
PLoS ONE, Vol 7, Iss 5, p e36438 (2012)
PLoS ONE; Vol 7
PLoS ONE, 7(5). Public Library of Science
PLoS ONE; 7(5) (2012)
Repisalud
Instituto de Salud Carlos III (ISCIII)
PLoS ONE, Vol 7, Iss 5, p e36438 (2012)
PLoS ONE; Vol 7
PLoS ONE, 7(5). Public Library of Science
BACKGROUND: Neutralizing antibodies provide markers for vaccine-induced protective immunity in many viral infections. By analogy, HIV-1 neutralizing antibodies induced by immunization may well predict vaccine effectiveness. Assessment of neutralizing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc97e4b0b814d52019898d662ae73c9a
https://hdl.handle.net/20.500.12105/6808
https://hdl.handle.net/20.500.12105/6808
Autor:
Julie M. Decker, Fang-Hua Lee, Amandeep K. Dhillon, Welkin E. Johnson, Robert W. Doms, T. Helen Donners, Douglas D. Richman, Guido Vanham, Dennis R. Burton, Ralph Pantophlet, George M. Shaw
Publikováno v:
Journal of virology
Attempts to elicit broadly neutralizing antibody responses by human immunodeficiency virus type 1 (HIV-1) vaccine antigens have been met with limited success. To better understand the requirements for cross-neutralization of HIV-1, we have characteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d564bca8c76a31a8627ac5f8fb019f4
https://europepmc.org/articles/PMC1900098/
https://europepmc.org/articles/PMC1900098/
Autor:
Katrien Fransen, Guido Vanham, Leo Heyndrickx, Tine Vermoesen, Helen Donners, Filip Van Wanzeele, Beatrijs Vandergucht, Peter Vanlandschoot, Sophia Steyaert, Lieven Verhoye, Geert Leroux-Roels
Publikováno v:
Antiviral research
Although a limited number of HIV-infected patients have broadly neutralizing antibodies, it has not been examined whether these antibodies can protect against infection with primary virus in vivo. Here we screened the plasma of 23 HIV-1-infected pati
Autor:
B. Willems, Guido Vanham, Guido van der Groen, Helen Donners, Susan W. Barnett, Lennart Åkerblom, Karin Lovgren-Bengtsson, Bror Morein, David Davis, Jonathan L. Heeney
Publikováno v:
Vaccine
Phase III efficacy trials of recombinant human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins were postponed. In Phase I and II trials these candidate vaccines had failed to induce neutralizing antibodies against virus which had been is
Publikováno v:
Journal of medical virology. 69(2)
HIV-1 infected individuals with cross-neutralizing antibodies against primary HIV-1 isolates belonging to Group M (envA-H) and O, are identified. To investigate the neutralization-kinetics of primary isolates with these antibodies, different neutrali
Autor:
Guido van der Groen, Helen Donners, Leo Heyndrickx, David Davis, Robert Colebunders, Tine Vermoesen, B. Willems
Publikováno v:
Journal of medical virology
The hypothesis is that there are neutralizing epitopes on the surface of free virions of human immunodeficiency virus type 1 (HIV-1) that correspond to the genetic subtype of the envelope glycoprotein. Assays with extended incubation and reduced abso
Autor:
Helen Donners, Robert Colebunders, Guido van der Groen, David Davis, B. Willems, Els Beirnaert
Publikováno v:
AIDS
Our results show that there is a difference in neutralization patterns between African and European plasma especially in African women. An attempt to generate human monoclonal antibodies from African women with broad cross-neutralizing capacity is on